<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6166924</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0204111</article-id><article-id pub-id-type="publisher-id">PONE-D-17-44542</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Thymidines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxicity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxicity</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neuropathy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Heredity</subject><subj-group><subject>Genetic Mapping</subject><subj-group><subject>Variant Genotypes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacogenetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Evolutionary Biology</subject><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Molecular Genetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Genetics</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Pharmacogenetic variation and sensory neuropathy related to d4T antiretroviral therapy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moketla</surname><given-names>Marvin Blessings</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wadley</surname><given-names>Antonia L.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kamerman</surname><given-names>Peter</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9342-2661</contrib-id><name><surname>de Assis Rosa</surname><given-names>Debra</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>School of Molecular and Cell Biology, Faculty of Science, University of the Witwatersrand, Johannesburg, South Africa</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Brain Function Research Group, School of Physiology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin University, Perth, Australia</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Gaunt</surname><given-names>Tom R.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Bristol, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>Debbie.deassisrosa@wits.ac.za</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>10</issue><elocation-id>e0204111</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>© 2018 Moketla et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Moketla et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0204111.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="2" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>The use of the HIV antiretroviral drug stavudine (d4T), a thymidine analogue, is associated with the development of mitochondrial toxicities such as sensory neuropathy (SN). </plain></SENT>
<SENT sid="4" pm="."><plain>Genetic variation in genes relating to d4T transport and metabolism, as well as genetic variation in the thymidine synthesis pathway, could influence occurrence of d4T-related toxicity. </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="5" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>We examined this hypothesis in a cohort of HIV-positive South African adults exposed to d4T, including 143 cases with SN and 120 controls without SN. </plain></SENT>
<SENT sid="7" pm="."><plain>Ten SNPs in four genes associated with stavudine transport, and 16 SNPs in seven genes of the thymidine synthesis / phosphorylation pathway were genotyped using Agena mass spectrometry methods. </plain></SENT>
<SENT sid="8" pm="."><plain>Associations between sensory neuropathy and genetic variants were evaluated using PLINK by univariate and multivariable analyses. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="9" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="10" pm="."><plain>Age and height were significantly associated with SN occurrence. </plain></SENT>
<SENT sid="11" pm="."><plain>Using logistic regression with age and height as covariates, and uncorrected empirical p-values, genetic variation in SLC28A1, SAMHD1, MTHFR and RRM2B was associated with SN in South Africans using d4T. </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="12" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>Variation in genes relating to d4T transport and metabolism, as well as genetic variation in the thymidine synthesis pathway may influence occurrence of d4T-related SN. </plain></SENT>
<SENT sid="14" pm="."><plain>These data contribute to the characterisation of African pharmacogenetic variation and its role in adverse response to antiretroviral therapy. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001321</institution-id><institution>National Research Foundation</institution></institution-wrap></funding-source><award-id>91513</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9342-2661</contrib-id><name><surname>de Assis Rosa</surname><given-names>Debra</given-names></name></principal-award-recipient></award-group><funding-statement>This work was funded by the National Research Foundation of South Africa (unrated researchers programme), grant no 91513 to DdAR, <ext-link ext-link-type="uri" xlink:href="http://www.nrf.ac.za">www.nrf.ac.za</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="3"/><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec005"><title><text><SENT sid="15" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>The use of antiretroviral therapy (ART) has changed the natural history of human immunodeficiency virus (HIV) infection into a manageable chronic disease requiring long-term treatment. </plain></SENT>
<SENT sid="17" pm="."><plain>ART stops or delays progression to AIDS by suppressing HIV viraemia to undetectable levels, thereby improving CD4+ T cell counts, and restoring immune function [1]. </plain></SENT>
<SENT sid="18" pm="."><plain>However despite the benefits of ART, a substantial percentage of treated individuals experience adverse drug reactions such as off-target toxicities and hypersensitivity reactions. </plain></SENT>
<SENT sid="19" pm="."><plain>For example, in South Africa, the thymidine analogue stavudine (d4T) that was used in a first line ART regimen from 2004 to 2010 [2, 3], was associated with high incidence of mitochondrial toxicities, including sensory neuropathy (SN), lactic acidosis, and lipodystrophy [4]. </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>Sensory neuropathy, the most frequent of the d4T adverse effects, is typically experienced as bilateral pain, pins-and-needles, and/or loss of sensation in a “stocking and glove” distribution on the body [5]. </plain></SENT>
<SENT sid="21" pm="."><plain>In two South African cohorts, more than half of individuals on d4T-containing regimens experienced SN [6, 7]. </plain></SENT>
<SENT sid="22" pm="."><plain>Drug-induced side effects often cause drug regimen switches. </plain></SENT>
<SENT sid="23" pm="."><plain>South Africans substituted d4T for other NRTIs in 21% of patients by three years of treatment [8] and in another study, at a high rate of 17.9 changes per 100 person-years [9] due to adverse d4T effects. </plain></SENT>
<SENT sid="24" pm="."><plain>Due to d4T’s toxicity profile, South African HIV treatment guidelines changed in 2010, in line with international recommendations, replacing d4T in the first line regimen with tenofovir [3]. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>Factors repeatedly associated with the development of SN after d4T use includes increased age and increased height [5]. </plain></SENT>
<SENT sid="26" pm="."><plain>But because not all individuals experience adverse drug reactions when treated with HIV antiretrovirals, there also may be a genetic predisposition to occurrence of side-effects. </plain></SENT>
<SENT sid="27" pm="."><plain>To date, investigations into genetic risk factors for SN have focused on genes related to mitochondrial function [10, 11] and inflammation [12, 13, 14]. </plain></SENT>
<SENT sid="28" pm="."><plain>However variation in the enzymes responsible for d4T transport and drug metabolism, which may influence susceptibility to d4T adverse reactions, has not yet been investigated. </plain></SENT>
<SENT sid="29" pm="."><plain>These “ADME” genes (affecting drug absorption, distribution, metabolism and elimination) [15] are often the focus of pharmacogenetic studies which aim to identify host genetic factors influencing drug efficacy and toxicity [16, 17]. </plain></SENT>
<SENT sid="30" pm="."><plain>Variation in ADME genes could influence d4T toxicity. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>Stavudine is transported into cells by the OAT1, CNT1, CNT3 and ENT3 membrane transporters [18–22], encoded by SLC22A1, SLC28A1, SLC28A3 and SLC29A3 genes respectively. </plain></SENT>
<SENT sid="32" pm="."><plain>Efflux is controlled by MDR1, BCRP and MRP5 transporters [18, 23] encoded by the ABCB1, ABCG2 and ABCG5 genes respectively. </plain></SENT>
<SENT sid="33" pm="."><plain>Intracellularly, stavudine-5’- triphosphate (d4T-TP), the active form of stavudine, is produced by sequential phosphorylation steps by the action of enzymes thymidine kinase, thymidylate kinase, and nucleoside diphosphate kinase [24], encoded by genes TK1, TK2, DTYMK and NME1. </plain></SENT>
<SENT sid="34" pm="."><plain>Enzymes of the UDP-glucuronosyltransferase (UGT) family perform phase II metabolism of d4T [24]. </plain></SENT>
<SENT sid="35" pm="."><plain>Variation in any of these ADME genes could potentially relate to d4T efficacy and toxicity. </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>The efficacy and toxicity of d4T (or d4T-TP) can also be influenced by the naturally occurring levels of thymidine triphosphate, with which d4T completes for incorporation into the nascent HIV DNA strand. </plain></SENT>
<SENT sid="37" pm="."><plain>Decreased endogenous deoxyribonucleotide pools result in higher incorporation of the NRTI phosphate [25] and could cause both increased NRTI efficacy and increased NRTI toxicity. </plain></SENT>
<SENT sid="38" pm="."><plain>Selvaraj et al. [26] found that HIV-positive individuals on ART who had clinical phenotypes associated with NRTI-induced mitochondrial toxicity, had lower ribonucleotide (RN) and deoxyribonucleotide (dRN) pools compared to infected individuals on ART who did not have mitochondrial toxicity. </plain></SENT>
<SENT sid="39" pm="."><plain>The amount of thymidine triphosphate (dTTP) present in a cell is governed by the rate of de novo and salvage thymidine synthesis and phosphorylation, and therefore by variation in enzymes along these pathways. </plain></SENT>
<SENT sid="40" pm="."><plain>Key enzymes of the thymidine de novo synthesis pathway include ribonucleotide reductase (RNR), nucleoside diphosphate kinase, dUTPase, thymidylate synthetase encoded by genes RRM1, RRM2, RRM2b, NME1, DUT and TYMS. </plain></SENT>
<SENT sid="41" pm="."><plain>The thymidine salvage and phosphorylation pathways involve the same enzymes that phosphorylate d4T (genes TK1, TK2, DTYMK and NME1). </plain></SENT>
<SENT sid="42" pm="."><plain>dTTP, but not d4T, is dephosphorylated by enzyme SAMHD1 [27]. </plain></SENT>
<SENT sid="43" pm="."><plain>The production of dTMP by thymidylate synthetase is tightly linked to the folate / methionine cycle, and therefore enzymes dihydrofolate reductase (DHFR) and 5,10-methylene-THF-reductase (MTHFR) also play a critical role in regulating thymidine production. </plain></SENT>
<SENT sid="44" pm="."><plain>Variation in any of these genes regulating thymidine synthesis could also potentially affect efficacy and toxicity of d4T. </plain></SENT>
</text></p><p><text><SENT sid="45" pm="."><plain>In summary, genetic variation in ADME genes relating to d4T transport and metabolism, as well as genetic variation in the thymidine synthesis pathways, could influence d4T-related toxicity. </plain></SENT>
<SENT sid="46" pm="."><plain>We examined this hypothesis in a black Southern African cohort exposed to d4T and phenotyped for sensory neuropathy, a common d4T-related toxicity. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec006"><title><text><SENT sid="47" pm="."><plain>Materials and methods </plain></SENT>
</text></title><sec id="sec007"><title><text><SENT sid="48" pm="."><plain>Study design and ethics statement </plain></SENT>
</text></title><p><text><SENT sid="49" pm="."><plain>Blood samples were collected from adults attending the Virology Clinic of the Charlotte Maxeke Johannesburg Academic Hospital, South Africa, between 2008 and 2009, as described in [7, 12]. </plain></SENT>
<SENT sid="50" pm="."><plain>Sample collection and genetics study protocols were approved by the Human Research Ethics Committee of the University of Witwatersrand (M080220 and M150459) and all participants gave written informed consent. </plain></SENT>
<SENT sid="51" pm="."><plain>Demographic data were collected, including ethnicity, age, gender and height. </plain></SENT>
<SENT sid="52" pm="."><plain>Participants who self-identified as black African and had no unrelated cause of neuropathy (such as diabetes or vitamin B12 deficiency) were included in genetic analyses. </plain></SENT>
<SENT sid="53" pm="."><plain>All participants had been exposed to d4T, had been on ART for at least six months, but were not necessarily using d4T at the time of sampling. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>SN in participants was assessed using the Brief Neuropathy Screening Tool [28] which is validated for the assessment of HIV-associated sensory neuropathy. </plain></SENT>
<SENT sid="55" pm="."><plain>This tool involved assessment of signs and symptoms of sensory neuropathy. </plain></SENT>
<SENT sid="56" pm="."><plain>Signs included absent ankle reflexes and reduced vibration sense in the great toe (using a 128Hz tuning fork, vibration sense of less than 10 seconds were regarded as reduced function), and symptoms included pain and paraesthesias (pins and needles, tingling and numbness). </plain></SENT>
<SENT sid="57" pm="."><plain>Sensory neuropathy was defined according to [28], namely the bilateral presence of at least one sign and one symptom. </plain></SENT>
</text></p></sec><sec id="sec008"><title><text><SENT sid="58" pm="."><plain>DNA extraction and genotyping </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>DNA was extracted from saliva in 39 samples using a QIAamp DNA mini kit (Qiagen) or from whole blood for the remainder of the samples using the salting out method [29]. </plain></SENT>
<SENT sid="60" pm="."><plain>Of the original 342 samples analysed by [12], 263 DNA samples were still available for use in the current study, including DNA from 143 cases with SN and 120 controls without SN. </plain></SENT>
<SENT sid="61" pm="."><plain>While 95% of the cohort were black South Africans, thirteen (5%) of the DNA samples were from individuals from neighbouring countries (Zimbabwe, Malawi or Mozambique). </plain></SENT>
<SENT sid="62" pm="."><plain>These samples were included in this study since black Africans speaking Bantu languages from all of these countries are considered to have similar genetic ancestry due to population migrations within the last 3 000 years [30]. </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>A total of 26 single nucleotide polymorphisms (SNPs) in twelve candidate genes were examined in this study. </plain></SENT>
<SENT sid="64" pm="."><plain>The genes included two genes encoding proteins that facilitate d4T entry into cells (SLC28A1, SLC28A3), two genes encoding proteins that facilitate d4T efflux from cells (ABCG2, ABCC5), and eight genes from the thymidine synthesis / d4T phosphorylation pathways (TK2, RRM1, RRM2, RRM2b, MTHFR, DHFR, SAMHD1, SLC19A1). </plain></SENT>
<SENT sid="65" pm="."><plain>Genes, and SNPs in these genes, were selected based on descriptions of SNP functional effects (such as changes in gene expression) or relevant phenotypic associations (such as association with adverse drug reactions) in the literature. </plain></SENT>
<SENT sid="66" pm="."><plain>SNPs were further selected if they had minor allele frequency &gt;5% in Kenyan Luhya samples from the 1000 Genomes database [31] and according to suitability for multiplex analysis on the genotyping platform. </plain></SENT>
<SENT sid="67" pm="."><plain>Genotyping was performed in two multiplexes using Agena MassArray mass spectrometry [32] at Inqaba Biotec (Pretoria, South Africa). </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="68" pm="."><plain>Statistical analyses </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>SNPs or DNA samples with &gt;10% missing data were excluded from analysis and Hardy-Weinberg equilibrium was assessed. </plain></SENT>
<SENT sid="70" pm="."><plain>Demographic characteristics in the cases vs. controls were compared by chi-squared or Mann-Whitney tests and significant differences were used as covariates in the multivariable analyses of genetic data. </plain></SENT>
<SENT sid="71" pm="."><plain>Allele, genotype and haplotype frequencies were assessed using gPLINK v.1.07 [33] and Haploview v.4.2 [34]. </plain></SENT>
<SENT sid="72" pm="."><plain>All possible 3-SNP haplotypes across each gene or chromosome under investigation were created using the sliding window option in gPLINK. </plain></SENT>
<SENT sid="73" pm="."><plain>Minor allele frequency (MAF) in Southern Africans was compared to MAF in Kenyan Luhya samples from the 1000 Genomes database using Fishers exact tests. </plain></SENT>
</text></p><p><text><SENT sid="74" pm="."><plain>The associations between sensory neuropathy and genetic variants (alleles, genotypes or haplotypes) were evaluated using gPLINK using chi-squared or Fishers tests for univariate analysis and using logistic regression for multivariable analysis. </plain></SENT>
<SENT sid="75" pm="."><plain>Two different P values were reported arising from logistic regression analyses: firstly, P values based on the logistic regression coefficient t-statistic and secondly, empirical P values calculated by the max(T) permutation method with 10 000 simulations,. </plain></SENT>
<SENT sid="76" pm="."><plain>Empirical P values (Pemp) less than 0.05 were considered statistically significant. </plain></SENT>
<SENT sid="77" pm="."><plain>These Pemp values are considered more robust than the t -test p values since permutation methods do not make distributional assumptions but rather generate the reference distribution of the tests statistic from the data. </plain></SENT>
<SENT sid="78" pm="."><plain>The logistic regression coefficient t- statistic data were used to calculate odds ratios and 95% confidence intervals, since this cannot be done using permutation methods. </plain></SENT>
<SENT sid="79" pm="."><plain>SNPs with OR&gt;1 were considered to be possible risk factors for SN occurrence, while SNPs with OR&lt;1 were considered to be protective. </plain></SENT>
<SENT sid="80" pm="."><plain>No corrections for multiple testing were considered in this exploratory study. </plain></SENT>
<SENT sid="81" pm="."><plain>All associations were tested as the minor allele compared with wild-type. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec010"><title><text><SENT sid="82" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec011"><title><text><SENT sid="83" pm="."><plain>Age and height are associated with HIV-SN after d4T use </plain></SENT>
</text></title><p><text><SENT sid="84" pm="."><plain>Characteristics of the study cohort are presented in Table 1. </plain></SENT>
<SENT sid="85" pm="."><plain>The comparison of demographic characteristics between cases and controls showed that increased age and increased height were significantly associated with SN occurrence in this cohort, as previously shown for the parent cohort [12]. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0204111.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204111.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="86" pm="."><plain>Demographic and clinical characteristics of the cohort. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0204111.t001g" xlink:href="pone.0204111.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>whole cohort </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Caseswith SN </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>Controlswithout SN </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>P value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>sample size </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>263 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>143 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>120 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>females, n (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>205 (78%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>110 (77%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>95 (79%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>0.333 </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>age, years (std dev) </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>38 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>41 (7.7) </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>36 (7.2) </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>&lt;0.0001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>height, cm (std dev) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>158.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>159.4 (8.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>156.4 (7.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>0.007 </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>weight, kg </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>68.61 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>69.56 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>67.49 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>0.231 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>body mass index (BMI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>27.55 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>27.45 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>27.66 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>0.970 </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>months since HIV diagnosis </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>52 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>54 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>49 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>0.538 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>Median CD4+ T-cell count at sampling (on ART) cells/μl </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>398 (27–1091) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>406(27–1091) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>393(45–1079) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>0.407 </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>Median CD4+ T-cell count nadir (pre-ART) cells/μl (range) </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>100 (1–403) </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>101 (1–253) </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>96 (2–403) </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>0.762 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>months on d4T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>0.770 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><text><SENT sid="141" pm="."><plain>All values are means unless otherwise indicated. </plain></SENT>
</text></p></fn><fn id="t001fn002"><p><text><SENT sid="142" pm="."><plain>n: sample size; std dev: standard deviation </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec012"><title><text><SENT sid="143" pm="."><plain>Characterisation of variation in thymidine synthesis and d4T ADME genes in black Southern Africans </plain></SENT>
</text></title><p><text><SENT sid="144" pm="."><plain>Genotyping was successful for all 26 SNPs in 243 samples after quality control procedures (134 cases and 109 controls), and all loci were in Hardy Weinberg equilibrium (P&gt;0.05). </plain></SENT>
<SENT sid="145" pm="."><plain>Minor allele frequencies (MAF) ranged from 0.021 (RRM1 rs12806698) to 0.477 (RRM1 rs1465952) as shown in Table 2. </plain></SENT>
<SENT sid="146" pm="."><plain>The MAF of seven SNPs in the Southern African cohort differed significantly (P&lt;0.05) from MAF in Kenya Luhya, including three SNPs in the d4T drug transporter gene and four SNPs in genes of the thymidine synthesis pathway, RRM2, RRM1 and TK2 (Table 2). </plain></SENT>
<SENT sid="147" pm="."><plain>The MAF for rs1801131 and rs1801133 in MTHFR reported here were also not significantly different from the MAF reported in a previous South African black cohort with unknown HIV infection status [35]. </plain></SENT>
<SENT sid="148" pm="."><plain>For the remainder of the SNPs, allele frequencies have not been reported previously in South or Southern African black populations. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0204111.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204111.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="149" pm="."><plain>Minor allele frequencies (MAF) in 243 black Southern Africans (SA) compared to MAF in 99 Luhya from Kenya (LWK). </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0204111.t002g" xlink:href="pone.0204111.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>Chromosome </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>Gene </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>SNP </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Major allele </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>Minor allele </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>MAF in SA(n = 243, 2n = 486) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>MAF in LWK (n = 99, 2n = 198) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>P value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>ABCC5 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>rs3749442 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>0.208 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>0.237 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>0.413 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>ABCG2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>rs2725252 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>0.193 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>0.222 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>0.402 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>ABCG2 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>rs2622604 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>C </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>T </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>0.132 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>0.126 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>0.901 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>ABCG2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>rs12505410 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>0.122 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>0.126 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>0.898 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>ABCG2 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>rs3114018 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>C </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>0.419 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>0.333 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>0.045 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>SLC28A3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>rs4877847 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>0.470 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>0.475 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>0.932 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>SLC28A3 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>rs7853758 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>0.5 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>0.303 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>&lt;0.0001 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>15 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>SLC28A1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>rs2242046 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>0.025 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>0.061 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>0.037 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>15 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>SLC28A1 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>rs2290272 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>0.242 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>0.172 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>0.053 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>15 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>SLC28A1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>rs8187758 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>0.155 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>0.131 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>0.477 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>11 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>RRM1 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>rs1465952 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>0.477 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>0.389 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>0.042 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>RRM1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>rs11030918 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>0.20 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>0.167 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>0.335 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>11 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>RRM1 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>rs12806698 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>C </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>0.021 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>0.015 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>0.766 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>RRM1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>rs1042927 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>0.181 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>0.263 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>0.021 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>RRM2 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>rs7574663 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>C </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>0.084 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>0.146 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>0.018 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>RRM2B </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>rs16918482 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>0.064 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>0.076 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>0.615 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>16 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>TK2 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>rs3743712 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>0.391 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>0.369 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>0.604 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>16 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>TK2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>rs11859474 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>0.263 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>0.293 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>0.449 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>16 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>TK2 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>rs2288399 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>0.152 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>0.081 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>0.012 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>MTHFR </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>rs1801131 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>0.144 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>0.187 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>0.165 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>1 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>MTHFR </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>rs1801133 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>0.070 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>0.071 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>1.000 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>DHFR </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>rs1650723 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>0.062 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>0.071 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>0.731 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>20 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>SAMHD1 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>rs8124728 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>0.169 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>0.152 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>0.649 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>20 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>SAMHD1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>rs1291142 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>G </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>0.231 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>0.237 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>0.921 </plain></SENT>
</text></td></tr><tr><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>20 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>SAMHD1 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>rs1891643 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>A </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>G </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>0.187 </plain></SENT>
</text></td><td align="center" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>0.207 </plain></SENT>
</text></td><td align="left" style="background-color:#C0C0C0" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>0.593 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>21 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>SLC19A1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>rs1051266 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>0.311 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>0.308 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>1.000 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><text><SENT sid="366" pm="."><plain>All SNPs are on forward strand. </plain></SENT>
<SENT sid="367" pm="."><plain>P values in bold indicate P&lt;0.05, Fisher’s exact test </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="368" pm="."><plain>Linkage disequilibrium (LD) was analysed in seven genes where more than one SNP was genotyped. </plain></SENT>
<SENT sid="369" pm="."><plain>Complete linkage (D’ = 1.000) was found among the following SNPs: rs1465952, rs11030918 and rs12806698 in RRM1; rs3743712 and rs11859474 in TK2; rs8124728, rs1291142 and rs1891643 in SAMHD1; rs12505410 and rs2725252 in ABCG2. </plain></SENT>
<SENT sid="370" pm="."><plain>In addition, D’ was 0.961 between rs2290272 and rs8187758 in SLC28A1. </plain></SENT>
<SENT sid="371" pm="."><plain>SNPs in MTHFR and in SLC28A3 were not in significant LD with each other (D’ &lt;0.3). </plain></SENT>
</text></p></sec><sec id="sec013"><title><text><SENT sid="372" pm="."><plain>Associations between ADME and thymidine synthesis genetic variants and sensory neuropathy </plain></SENT>
</text></title><p><text><SENT sid="373" pm="."><plain>For all SNPs in univariate analyses, the minor allele frequency did not differ significantly between cases and controls. </plain></SENT>
<SENT sid="374" pm="."><plain>SLC28A1 rs8187758 and SAMHD1 r8124728 were significantly associated with SN in univariate genotypic models (Pemp = 0.011 and Pemp = 0.038, Table 3). </plain></SENT>
<SENT sid="375" pm="."><plain>In multivariable analyses taking age and height into account, rs8187758 in SLC28A1 was no longer significantly associated with SN. </plain></SENT>
<SENT sid="376" pm="."><plain>Variation in SAMHD1 remained associated with SN in multivariable analysis, including rs8124728 (Pemp = 0.013), rs1891643 (Pemp = 0.017) and haplotype GGA (Pemp = 0.015, Table 3). </plain></SENT>
<SENT sid="377" pm="."><plain>Two SNPs in the thymidine synthesis pathway, rs1801131 in MTHFR and rs16918482 in RRM2B were associated with SN in a multivariable genotypic and recessive models (Pemp = &lt;0.002, Table 3). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0204111.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0204111.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="378" pm="."><plain>Gene polymorphisms significantly associated with SN after d4T use. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0204111.t003g" xlink:href="pone.0204111.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>Gene </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>SNP </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>Univariate analysis Pemp value 1 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>Model of association </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>Multivariable analysis Pemp value1,2 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>Multivariable analysis P value2, 3 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>OR in multivariable analysis (95% CI) 4 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>(Minor allele) direction of effect </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>SLC28A1 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>rs8187758 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>0.011 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>genotypic </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>0.249 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>0.060 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>1.89 (0.61–5.86) </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>(A) risk </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>SAMHD1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>rs8124728 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>0.038 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>genotypic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>0.018 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>0.709 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>0.45 (0.19–1.05) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>(A) protective </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>SAMHD1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>rs8124728 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>0.092 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>recessive </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>0.014 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>0.047 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>0.18 (0.03–0.98) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>(A) protective </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>SAMHD1 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>rs1891643 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>0.280 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>recessive </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>0.025 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>0.075 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>5.08 (0.85–30.44) </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>(G) risk </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>SAMHD1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>rs8124728, rs1291142, rs1891643 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>0.073 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>haplotype GGA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>0.015 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>0.048 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>0.33 (0.07–0.98) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>(GGA) protective </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>MTHFR </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>rs1801131 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>0.198 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>recessive </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>0.001 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>0.146 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>0.12 (0.01–2.07) </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>(G) protective </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>MTHFR </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>rs1801131 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>0.244 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>genotypic </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>0.002 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>0.224 </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>0.33 (0.08–1.39) </plain></SENT>
</text></td><td align="left" style="background-color:#BFBFBF" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>(G) protective </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>RRM2B </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>rs16918482 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>0.509 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>recessive </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>0.0003 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>0.772 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>0.65 (0.04–11.60) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>(C) protective </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>RRM2B </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>rs16918482 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>0.416 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>genotypic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>0.002 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>0.954 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>0.81 (0.19–3.26) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>(C) protective </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><text><SENT sid="459" pm="."><plain>1 Pemp values were from permutation analysis during multiple logistic regression using 10 000 simulations; Uncorrected Pemp values &lt; 0.05 were considered significant and are shown in bold. </plain></SENT>
</text></p></fn><fn id="t003fn002"><p><text><SENT sid="460" pm="."><plain>2 multivariable tests took into account age and height as covariates </plain></SENT>
</text></p></fn><fn id="t003fn003"><p><text><SENT sid="461" pm="."><plain>3 P values were standard results from coefficient t-tests during multiple logistic regression and were used to calculate OR and direction of effect. </plain></SENT>
</text></p></fn><fn id="t003fn004"><p><text><SENT sid="462" pm="."><plain>4 OR: odds ratio; CI: confidence interval </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="463" pm="."><plain>These Pemp values were not corrected for multiple testing and may therefore be false positives; we have used them as hypothesis- generating associations. </plain></SENT>
<SENT sid="464" pm="."><plain>The Pemp values calculated using permutation models were considered more robust than the p values used for calculation of odds ratios (Table 3). </plain></SENT>
<SENT sid="465" pm="."><plain>Considering the odds ratios generated during logistic regression, the recessive genotype of SAMHD1 rs1891643 may be considered as a possible risk factor for SN occurrence (OR = 5.089) whereas all other genotypes described above as significant in multivariable analysis may be protective against SN (OR&lt;1, Table 3). </plain></SENT>
<SENT sid="466" pm="."><plain>Weak effect sizes were noted for these loci. </plain></SENT>
<SENT sid="467" pm="."><plain>The complete results for multivariable analysis can be found in S1 Table. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec014"><title><text><SENT sid="468" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="469" pm="."><plain>Pharmacogenetics is concerned with characterising individual genetic variability and understanding how it affects response to, and side-effects arising from treatment. </plain></SENT>
<SENT sid="470" pm="."><plain>We explored variation in d4T ADME genes, and variation in genes of the thymidine synthesis pathway, and their association with SN in a cohort of HIV-positive South African adults treated with d4T-containing ART. </plain></SENT>
<SENT sid="471" pm="."><plain>We found that genetic variants of the SLC28A1, SAMHD1, MTHFR and RRM2B genes were associated with SN in this cohort using uncorrected Pemp values. </plain></SENT>
<SENT sid="472" pm="."><plain>This is the first report of associations between genetic variation in SAMHD1 and RRM2B and ART-induced toxicity. </plain></SENT>
<SENT sid="473" pm="."><plain>Our findings support previously reported associations between variation in SLC28A1 and MTHFR and toxicity of ART. </plain></SENT>
</text></p><p><text><SENT sid="474" pm="."><plain>SLC28A1 encodes the CNT1 membrane transport protein which assists with d4T influx into the cell. </plain></SENT>
<SENT sid="475" pm="."><plain>A previous study found an association in Ethiopians between variation in SLC28A1 and dose-toxicity of zidovudine (AZT), another thymidine analogue used in ART [36]. </plain></SENT>
<SENT sid="476" pm="."><plain>However the associated variant in that study was rs2242046, which was not associated with SN in the current study, and not in linkage with significant SNPs in the current study. </plain></SENT>
<SENT sid="477" pm="."><plain>In this study, SLC28A1 SNP rs8187758 was associated in univariate analysis, but not multivariable analysis, with SN occurrence. </plain></SENT>
<SENT sid="478" pm="."><plain>This SNP has been previously reported to increase thymidine uptake [37], but its effect on d4T is not known. </plain></SENT>
<SENT sid="479" pm="."><plain>If only thymidine uptake and not d4T uptake is increased, this should potentially cause decreased d4T toxicity, however if this SNP also increases d4T influx then the protective effect would be ablated. </plain></SENT>
<SENT sid="480" pm="."><plain>SNP rs8187758 was in high LD with rs2290272 in our cohort, which has been shown to cause reduced expression of CNT1 and lowered affinity for substrates [38]; the effects of combinations of these SNPs on d4T uptake is not known. </plain></SENT>
</text></p><p><text><SENT sid="481" pm="."><plain>The SAMHD1 enzyme dephosphorylates dTTP but does not hydrolyse active d4T back to its unphosphorylated form [27]. </plain></SENT>
<SENT sid="482" pm="."><plain>SAMHD1 activity may therefore increase efficacy or toxicity of thymidine analogues by reducing competition with intracellular dNTP [39]. </plain></SENT>
<SENT sid="483" pm="."><plain>We found significant associations between SAMHD1 genotypes and haplotypes involving SNPs rs8124728 and rs1891643, and SN in our cohort in both univariate and multivariable analyses. </plain></SENT>
<SENT sid="484" pm="."><plain>These SNPs are located in an intron and the 3’ UTR of the gene respectively with unknown function. </plain></SENT>
<SENT sid="485" pm="."><plain>They were in complete LD with rs1291142, a SNP described as causing decreased SAMHD1 expression [40]. </plain></SENT>
<SENT sid="486" pm="."><plain>However rs1291142 itself was not found to be associated with SN in this study, and SNP rs1891643 was seen to cause a 5-fold increase in SN risk, not a decrease in risk as would be expected from decreased SAMHD1 expression. </plain></SENT>
<SENT sid="487" pm="."><plain>Further work is required to understand the functional cause of the SAMHD1 SNP associations with SN observed in this study. </plain></SENT>
</text></p><p><text><SENT sid="488" pm="."><plain>Domingo et al. [41, 42] found associations in Caucasians between low expression TYMS genotypes in combination with MTHFR polymorphisms, and the development of several d4T-related toxicities, including lipodystrophy, sensory neuropathy and pancreatitis. </plain></SENT>
<SENT sid="489" pm="."><plain>They hypothesized that normal / high levels of MTHFR would cause decreased levels of thymidylate synthetase (causing lower de novo thymidine production) and therefore increased d4T toxicity, while low levels of MTHFR could associate with decreased d4T toxicity [41]. </plain></SENT>
<SENT sid="490" pm="."><plain>Our results showed a significant association between MTHFR SNP rs1801131 and SN, supporting the suggestion of a role of variation in this gene and ART toxicity. </plain></SENT>
<SENT sid="491" pm="."><plain>SNP rs1801131 or A1298C causes a glu429-to-ala (E429A) substitution which decreases MTHFR activity [43], which theoretically would cause increased thymidylate synthetase levels and decreased d4T toxicity. </plain></SENT>
<SENT sid="492" pm="."><plain>This is consistent with our finding of a protective effect of rs1801131 against SN. </plain></SENT>
</text></p><p><text><SENT sid="493" pm="."><plain>Ribonucleotide reductase (RNR) catalyses the formation of deoxyribonucleotides from ribonucleotides [44] and therefore plays a critical role in de novo DNA synthesis and cell proliferation The tetrameric enzyme is composed of large RNR1 and small RNR2 subunits encoded by the RRM1 or RRM2 genes. </plain></SENT>
<SENT sid="494" pm="."><plain>The RNR2b isoform encoded by the RRM2B gene is induced by p53 and controls mtDNA synthesis in non-proliferating cells [45]. </plain></SENT>
<SENT sid="495" pm="."><plain>We found an association between RRM2B SNP rs16918482 and SN in a multivariable model. </plain></SENT>
<SENT sid="496" pm="."><plain>This SNP is in the 3’ UTR of the gene with no known function. </plain></SENT>
<SENT sid="497" pm="."><plain>In the 1000 genomes data from the Luhya from Kenya, this SNP tagged 25 other SNPs in RRM2B and further work to identify the causal variant underlying association with SN is required. </plain></SENT>
<SENT sid="498" pm="."><plain>Other mutations in RRM2B are known to exist that cause severe mtDNA depletion [45], which is also a characteristic of ART-induced mitochondrial toxicities. </plain></SENT>
</text></p><p><text><SENT sid="499" pm="."><plain>The current study also documents the frequencies of ten ADME variants and 16 variants in the thymidine synthesis pathway in the South African black population and adds to the growing literature on the pharmacogenetic characterization of African populations [46]. </plain></SENT>
<SENT sid="500" pm="."><plain>To our knowledge, this is the first report on frequencies for 25 of these SNPs in Bantu-speaking Southern Africans. </plain></SENT>
<SENT sid="501" pm="."><plain>Genetic studies in South Africans are especially important given the high level of genetic diversity and low levels of linkage disequilibrium that exist in South African populations [47], and because, despite shared genetic ancestry, data in existing Hapmap populations cannot be directly extrapolated to represent South African populations. </plain></SENT>
</text></p><p><text><SENT sid="502" pm="."><plain>This study had several weaknesses. </plain></SENT>
<SENT sid="503" pm="."><plain>The sample size was relatively small. </plain></SENT>
<SENT sid="504" pm="."><plain>Without statistical correction for multiple testing, it is possible some of these findings are false positives. </plain></SENT>
<SENT sid="505" pm="."><plain>The SNPs identified in this study had weak effect sizes and may act in combination with other risk alleles for SN previously identified in this cohort [12–14]. </plain></SENT>
<SENT sid="506" pm="."><plain>The findings in this study may not be easily replicated nor relevant to d4T treatment tailoring since d4T has been phased out of use in South Africa and globally. </plain></SENT>
<SENT sid="507" pm="."><plain>However the ADME variants described here may play a role in efficacy and toxicity of other antiretroviral drugs that are transported by the same drug transporters. </plain></SENT>
<SENT sid="508" pm="."><plain>Our data for the thymidine synthesis pathway may contribute to further understanding of pharmacogenetics of other thymidine analogues such as those used in treatment of hepatitis B or cancer, or pharmacogenetics of other treatments such as folate or uridine supplements. </plain></SENT>
<SENT sid="509" pm="."><plain>In addition, whilst pharmacogenetics is often used to identify individuals at high risk of side effects, it could also offer the potential to identify individuals who can safely use drugs that otherwise are considered toxic, such as d4T. </plain></SENT>
</text></p><p><text><SENT sid="510" pm="."><plain>In conclusion, variation in genes relating to d4T transport and metabolism, as well as genetic variation in the thymidine synthesis pathway may influence occurrence of d4T-related SN. </plain></SENT>
<SENT sid="511" pm="."><plain>These data contribute to the characterization of African pharmacogenetic variation and its role in adverse response to antiretroviral therapy. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec015"><title><text><SENT sid="512" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0204111.s001"><label>S1 Table</label><caption><title><text><SENT sid="513" pm="."><plain>Associations of 26 SNPs with SN in multivariable models, calculated in gPLINK using logistic regression taking into account age and height. </plain></SENT>
</text></title><p><text><SENT sid="514" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0204111.s001.docx"><caption><p><text><SENT sid="515" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="516" pm="."><plain>We wish to thank the staff and the patients of the Virology Clinic in the Charlotte Maxeke Johannesburg Academic Hospital and Florence Mtsweni for acting as the interpreter for the study. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0204111.ref001"><text><SENT sid="517" pm="."><plain>1VolberdingPA and DeeksSG. Antiretroviral therapy and management of HIV infection. Lancet. 2010; 376(9734): 49–62. 10.1016/S0140-6736(10)60676-9 <?supplied-pmid 20609987?>20609987 </plain></SENT>
</text></ref><ref id="pone.0204111.ref002"><text><SENT sid="518" pm="."><plain>2National Antiretroviral Treatment Guidelines, first edition. </plain></SENT>
<SENT sid="519" pm="."><plain>2004. </plain></SENT>
<SENT sid="520" pm="."><plain>South African National Department of Heath. </plain></SENT>
<SENT sid="521" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/medicinedocs/documents/s17758en/s17758en.pdf">http://apps.who.int/medicinedocs/documents/s17758en/s17758en.pdf</ext-link>. </plain></SENT>
</text></ref><ref id="pone.0204111.ref003"><text><SENT sid="522" pm="."><plain>3National Antiretroviral Treatment Guidelines, 2010. </plain></SENT>
<SENT sid="523" pm="."><plain>South African National Department of Heath. </plain></SENT>
<SENT sid="524" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/medicinedocs/documents/s19153en/s19153en.pdf">http://apps.who.int/medicinedocs/documents/s19153en/s19153en.pdf</ext-link>. </plain></SENT>
</text></ref><ref id="pone.0204111.ref004"><text><SENT sid="525" pm="."><plain>4MenezesCN, MaskewM, SanneI, CrowtherNJ and RaalFJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis 2011; 11: 244–254. 10.1186/1471-2334-11-244 <?supplied-pmid 21923929?>21923929 </plain></SENT>
</text></ref><ref id="pone.0204111.ref005"><text><SENT sid="526" pm="."><plain>5KamermanPR, WadleyAL, CherryCL. HIV-associated sensory neuropathy: risk factors and genetics. Curr. </plain></SENT>
<SENT sid="527" pm="."><plain>Pain Headache Rep. 2012;16:226–236. 10.1007/s11916-012-0257-z <?supplied-pmid 22367397?>22367397 </plain></SENT>
</text></ref><ref id="pone.0204111.ref006"><text><SENT sid="528" pm="."><plain>6MaritzJ, BenatarM, DaveJA, HarrisonTB, BadriM, LevittNS et al HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 2010; 41(5): 599–606. 10.1002/mus.21535 <?supplied-pmid 20229576?>20229576 </plain></SENT>
</text></ref><ref id="pone.0204111.ref007"><text><SENT sid="529" pm="."><plain>7WadleyAL, CherryCL, PriceP and KamermanPR. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J Pain Symptom Manage 2011; 41(4): 700–706. 10.1016/j.jpainsymman.2010.07.006 <?supplied-pmid 21145196?>21145196 </plain></SENT>
</text></ref><ref id="pone.0204111.ref008"><text><SENT sid="530" pm="."><plain>8BoulleA, OrrelC, KaplanR, Van CutsemG, McNallyM, HilderbrandK, et al Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12(5):753–60. <?supplied-pmid 17713158?>17713158 </plain></SENT>
</text></ref><ref id="pone.0204111.ref009"><text><SENT sid="531" pm="."><plain>9NjugunaC, OrrellC, KaplanR, BekkerL-G, WoodR, LawnSD. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of Tenofovir. PLoS One. 2013; 8(5): e63596 10.1371/journal.pone.0063596 <?supplied-pmid 23717451?>23717451 </plain></SENT>
</text></ref><ref id="pone.0204111.ref010"><text><SENT sid="532" pm="."><plain>10KampiraE, KumwendaJ, van OosterhoutJJ, DandaraC. Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in Malawian adults on stavudine containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2013, 63:647–652. 10.1097/QAI.0b013e3182968ea5 <?supplied-pmid 23614993?>23614993 </plain></SENT>
</text></ref><ref id="pone.0204111.ref011"><text><SENT sid="533" pm="."><plain>11SinxadiPZ, DaveJA, SamuelsDC, HeckmannJM, MaartensG, LevittNS et al Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study. AIDS Res Hum Retroviruses, 2013, 29(7): 1031–1039. 10.1089/AID.2012.0373 <?supplied-pmid 23428049?>23428049 </plain></SENT>
</text></ref><ref id="pone.0204111.ref012"><text><SENT sid="534" pm="."><plain>12WadleyAL, KamermanPR, ChewCSN, LombardZ, CherryC, PriceP. A polymorphism in IL4 may associate with sensory neuropathy in African HIV patients. Mol Immunol, 2013; 55(3), pp. 197–199.23511027 </plain></SENT>
</text></ref><ref id="pone.0204111.ref013"><text><SENT sid="535" pm="."><plain>13WadleyAL, HendryLM, KamermanPR, ChewCSN, PriceP, CherryCL et al Role of TNF block genetic variants in HIV-associated sensory neuropathy in black Southern Africans. Eur. </plain></SENT>
<SENT sid="536" pm="."><plain>J. </plain></SENT>
<SENT sid="537" pm="."><plain>Hum. </plain></SENT>
<SENT sid="538" pm="."><plain>Genet. 2015;23:363–368. 10.1038/ejhg.2014.104 <?supplied-pmid 24896147?>24896147 </plain></SENT>
</text></ref><ref id="pone.0204111.ref014"><text><SENT sid="539" pm="."><plain>14GoulleeH, WadleyAL, CherryCL, AllcockRJN, BlackM, KamermanPR et al Polymorphisms in CAMKK2 may predict sensory neuropathy in African HIV patients. J. Neurovirol. 2016;22:508–517. 10.1007/s13365-015-0421-4 <?supplied-pmid 26785644?>26785644 </plain></SENT>
</text></ref><ref id="pone.0204111.ref015"><text><SENT sid="541" pm="."><plain>15KerbR, FuxR, MörikeK, KremsnerPG, GilJP, GleiterCH et al Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis. 2009; 9(12): 760–774. 10.1016/S1473-3099(09)70320-2 <?supplied-pmid 19926036?>19926036 </plain></SENT>
</text></ref><ref id="pone.0204111.ref016"><text><SENT sid="542" pm="."><plain>16JohnsonJA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet. 2003; 19(11): 660–666 10.1016/j.tig.2003.09.008 <?supplied-pmid 14585618?>14585618 </plain></SENT>
</text></ref><ref id="pone.0204111.ref017"><text><SENT sid="543" pm="."><plain>17MichaudV, Bar-MagenT, TurgeonJ, FlockhartD, DestaZ, WainbergMA. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev. 2012; 64(3): 803–833. 10.1124/pr.111.005553 <?supplied-pmid 22759796?>22759796 </plain></SENT>
</text></ref><ref id="pone.0204111.ref018"><text><SENT sid="544" pm="."><plain>18Pastor-AngladaM, Cano-SoldadoP, Molina-ArcasM, LostaoMP, LarráyozI, Martínez-PicadoJ. et al Cell entry and export of nucleoside analogues. Virus Res. 2005; 107(2): 151–164. 10.1016/j.virusres.2004.11.005 <?supplied-pmid 15649561?>15649561 </plain></SENT>
</text></ref><ref id="pone.0204111.ref019"><text><SENT sid="545" pm="."><plain>19ChanLM, LowesS, HirstBH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004; 21(1): 25–51. <?supplied-pmid 14706810?>14706810 </plain></SENT>
</text></ref><ref id="pone.0204111.ref020"><text><SENT sid="546" pm="."><plain>20MinuesaG, Huber-RuanoI, Pastor-AngladaM, KoepsellH, ClotetB, Martinez-PicadoJ. Drug uptake transporters in antiretroviral therapy. Pharmacol Ther. 2011; 132(3): 268–279. 10.1016/j.pharmthera.2011.06.007 <?supplied-pmid 21816170?>21816170 </plain></SENT>
</text></ref><ref id="pone.0204111.ref021"><text><SENT sid="547" pm="."><plain>21Molina-ArcasM, CasadoFJ, Pastor-AngladaM. Nucleoside transporter proteins. Curr Vasc Pharmacol. 2009; 7(4): 426–434. <?supplied-pmid 19485885?>19485885 </plain></SENT>
</text></ref><ref id="pone.0204111.ref022"><text><SENT sid="548" pm="."><plain>22Cano‐SoldadoP and Pastor‐AngladaM. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med Res Rev. 2012; 32(2): 428–457. 10.1002/med.20221 <?supplied-pmid 21287570?>21287570 </plain></SENT>
</text></ref><ref id="pone.0204111.ref023"><text><SENT sid="549" pm="."><plain>23KisO, RobillardK, ChanGN, BendayanR. The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010; 31(1): 22–35. 10.1016/j.tips.2009.10.001 <?supplied-pmid 20004485?>20004485 </plain></SENT>
</text></ref><ref id="pone.0204111.ref024"><text><SENT sid="550" pm="."><plain>24AndradeCH, de FreitasLM, de OliveiraV. Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism. Braz J Pharm Sci. 2010; 47 (2): 209–230 </plain></SENT>
</text></ref><ref id="pone.0204111.ref025"><text><SENT sid="551" pm="."><plain>25RampazzoC, MiazziC, FranzolinE, PontarinG, FerraroP, FranginiM et al Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances. Mutat Res 2010; 703: 2–10 10.1016/j.mrgentox.2010.06.002 <?supplied-pmid 20561600?>20561600 </plain></SENT>
</text></ref><ref id="pone.0204111.ref026"><text><SENT sid="552" pm="."><plain>26SelvarajS, GhebremichaelM, LiM, FoliY, Langs‐BarlowA, OgbuaguA et al Antiretroviral therapy–induced mitochondrial toxicity: potential mechanisms beyond polymerase‐γ inhibition. Clin PharmacolTher. 2014; 96(1): 110–120. </plain></SENT>
</text></ref><ref id="pone.0204111.ref027"><text><SENT sid="553" pm="."><plain>27BallanaE, BadiaR, TerradasG, Torres-TorronterasJ, RuizA, PaulsE, et al SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2014; 58(8):4804–13 10.1128/AAC.03145-14 <?supplied-pmid 24913159?>24913159 </plain></SENT>
</text></ref><ref id="pone.0204111.ref028"><text><SENT sid="554" pm="."><plain>28CherryCL, WesselinghSL, LalL, McArthurJC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology. 2005; 65(11): 1778–1781. 10.1212/01.wnl.0000187119.33075.41 <?supplied-pmid 16344522?>16344522 </plain></SENT>
</text></ref><ref id="pone.0204111.ref029"><text><SENT sid="555" pm="."><plain>29MillerS, DykesD, PoleskyH. A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res. 1998; 16: 215. </plain></SENT>
</text></ref><ref id="pone.0204111.ref030"><text><SENT sid="556" pm="."><plain>30de FilippoC, BostoenK, StonekingM, PakendorfB. Bringing together linguistic and genetic evidence to test the Bantu expansion. Proc. </plain></SENT>
<SENT sid="557" pm="."><plain>R. </plain></SENT>
<SENT sid="558" pm="."><plain>Soc. </plain></SENT>
<SENT sid="559" pm="."><plain>Lond. 2012; B279,3256–3263 </plain></SENT>
</text></ref><ref id="pone.0204111.ref031"><text><SENT sid="560" pm="."><plain>31The 1000 Genomes Project Consortium. </plain></SENT>
<SENT sid="561" pm="."><plain>An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65. </plain></SENT>
<SENT sid="562" pm="."><plain>Data available at <ext-link ext-link-type="uri" xlink:href="http://browser.1000genomes.org/index.html">http://browser.1000genomes.org/index.html</ext-link>. 10.1038/nature11632 <?supplied-pmid 23128226?>23128226 </plain></SENT>
</text></ref><ref id="pone.0204111.ref032"><text><SENT sid="563" pm="."><plain>32GabrielS, ZiaugraL, TabbaaD. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009; 60:2.12.1–2.12.18 </plain></SENT>
</text></ref><ref id="pone.0204111.ref033"><text><SENT sid="564" pm="."><plain>33PurcellS, NealeB, Todd-BrownK, ThomasL, FerreiraMAR, BenderD et al PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet. 2007; 81(3):559–75. </plain></SENT>
<SENT sid="565" pm="."><plain>Software available at <ext-link ext-link-type="uri" xlink:href="http://pngu.mgh.harvard.edu/purcell/PLINK/">http://pngu.mgh.harvard.edu/purcell/PLINK/</ext-link>. 10.1086/519795 <?supplied-pmid 17701901?>17701901 </plain></SENT>
</text></ref><ref id="pone.0204111.ref034"><text><SENT sid="566" pm="."><plain>34BarrettJC, FryB, Maller JDMJ, Daly MJ. </plain></SENT>
<SENT sid="567" pm="."><plain>Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21(2), pp.263–265. 10.1093/bioinformatics/bth457 <?supplied-pmid 15297300?>15297300 </plain></SENT>
</text></ref><ref id="pone.0204111.ref035"><text><SENT sid="568" pm="."><plain>35ScholtzCL, OdendaalHJ, ThiartR, LoubserL, HillermannR, DelportR et al Analysis of two mutations in the MTHFR gene associated with mild hyperhomocysteinaemia–heterogeneous distribution in the South African population. S Afr Med J, 2002; 92(6): 464–467. <?supplied-pmid 12146133?>12146133 </plain></SENT>
</text></ref><ref id="pone.0204111.ref036"><text><SENT sid="569" pm="."><plain>36Tekola-AyeleF, AdeyemoA, AseffaA, HailuE, FinanC, DaveyG, et al Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. Pharmacogenomics J, 2015; 15(1): 101–108. 10.1038/tpj.2014.39 <?supplied-pmid 25069476?>25069476 </plain></SENT>
</text></ref><ref id="pone.0204111.ref037"><text><SENT sid="570" pm="."><plain>37Errasti-MurugarrenE, Pastor-AngladaM. Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics. 2010; 11(6): 809–841. 10.2217/pgs.10.70 <?supplied-pmid 20504255?>20504255 </plain></SENT>
</text></ref><ref id="pone.0204111.ref038"><text><SENT sid="571" pm="."><plain>38KroetzDL, Yee SW, Giacomini KM. </plain></SENT>
<SENT sid="572" pm="."><plain>The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther. 2010; 87(1): 109–116. 10.1038/clpt.2009.226 <?supplied-pmid 19940846?>19940846 </plain></SENT>
</text></ref><ref id="pone.0204111.ref039"><text><SENT sid="573" pm="."><plain>39AmieSM, DalyMB, NobleE, SchinaziRF, BambaraRA, KimB. Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. Biol Chem 2013; 288(28): 20683–20691. </plain></SENT>
</text></ref><ref id="pone.0204111.ref040"><text><SENT sid="574" pm="."><plain>40CoonS, WangD, WuL. Polymorphisms of the SAMHD1 gene are not associated with the infection and natural control of HIV type 1 in Europeans and African-Americans. AIDS Res Hum Retroviruses. 2012; 28(12): 1565–1573. 10.1089/AID.2012.0039 <?supplied-pmid 22530776?>22530776 </plain></SENT>
</text></ref><ref id="pone.0204111.ref041"><text><SENT sid="575" pm="."><plain>41DomingoP, del Carmen CabezaM, TorresF, SalazarJ, del Mar GutierrezM, MateoMG et al Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy. PloS One, 2013; 8(2): e57347 10.1371/journal.pone.0057347 <?supplied-pmid 23468971?>23468971 </plain></SENT>
</text></ref><ref id="pone.0204111.ref042"><text><SENT sid="576" pm="."><plain>42DomingoP, MateoMG, PruvostA, TorresF, SalazarJ, del Mar GutierrezM. et al Polymorphisms of pyrimidine pathway enzymes encoding genes and HLA-B* 40∶01 carriage in stavudine-associated lipodystrophy in HIV-infected patients. PloS One. 2013; 8(6): e67035 10.1371/journal.pone.0067035 <?supplied-pmid 23840581?>23840581 </plain></SENT>
</text></ref><ref id="pone.0204111.ref043"><text><SENT sid="577" pm="."><plain>43van der PutNMJ, GabreelsF, StevensEMB, SmeitinkJAM, TrijbelsFJM, EskesTKAB, et al A second common mutation in the methylene tetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. </plain></SENT>
<SENT sid="578" pm="."><plain>J. </plain></SENT>
<SENT sid="579" pm="."><plain>Hum. </plain></SENT>
<SENT sid="580" pm="."><plain>Genet. 1998; 62:1044–1051 10.1086/301825 <?supplied-pmid 9545395?>9545395 </plain></SENT>
</text></ref><ref id="pone.0204111.ref044"><text><SENT sid="581" pm="."><plain>44ElledgeSJ, ZhouZ, AllenJB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem. </plain></SENT>
<SENT sid="582" pm="."><plain>Sci. 1992; 17 (3): 119–23. <?supplied-pmid 1412696?>1412696 </plain></SENT>
</text></ref><ref id="pone.0204111.ref045"><text><SENT sid="583" pm="."><plain>45BourdonA, MinaiL, SerreV, JaisJP, SarziE, AubertS, et al Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007; 39(6):776–80. 10.1038/ng2040 <?supplied-pmid 17486094?>17486094 </plain></SENT>
</text></ref><ref id="pone.0204111.ref046"><text><SENT sid="584" pm="."><plain>46DandaraC, LombardZ, Du PlooyI, McLellanT, NorrisSA, RamsayM. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics. 2011;12(12):1663–70. 10.2217/pgs.11.106 <?supplied-pmid 22118051?>22118051 </plain></SENT>
</text></ref><ref id="pone.0204111.ref047"><text><SENT sid="585" pm="."><plain>47WarnichL, DrogemollerBS, PepperM, DandaraC, WrightG. Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Person Med. 2011; 9 (3): 191–207 10.2174/187569211796957575 <?supplied-pmid 22563365?>22563365 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
